Generate Biomedicines (GENB) priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Goldman Sachs and Morgan Stanley are acting as joint book running managers for the offering. Generate Biomedicines is a clinical-stage generative biology company that says it is “pioneering the AI revolution in biotechnology and drug design and development.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENB: